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NO/cGMP signaling is essential for normal brain function,
including learning and memory, and mediation of long-
term potentiation (LTP). NO/cGMP signaling is coupled
to cholinergic, glutamatergic, and dopaminergic systems
and plays key roles in motor function associated with
Parkinson’s disease pathogenesis and L-DOPA therapy. In
Alzheimer’s Disease (AD), early synaptic failure, has been
linked to dysfunction of gene expression programs
mediated via the transcription factor cAMP-response ele-
ment binding protein (CREB), activation of which is tightly
regulated by NO/cGMP. Since several neurodegenerative
disorders continue to be dogmatically linked to the chemi-
cal toxicity of NO, activation of soluble guanylyl cyclase
(sGC) represents a potential therapeutic approach in both
AD and PD; whereas negative modulation of sGC may be
of use in some stages of PD. Such small molecule sGC
modulators (GCMs) can be assayed in cell cultures by
measuring levels of phosphorylated CREB (pCREB).
GCMs that allosterically potentiate NO activation of sGC
have proven successful in clinical trials for peripheral indi-
cations, however, there are no reports directed at thera-
peutic activity in the CNS. The aim of this study is to
develop GCMs for use in CNS disorders, including AD
and PD. A library of GCMs was synthesized, including
positive allosteric modulators (PAMs) and negative modu-
lators, as assessed by increasing levels of pCREB in SH-
SY5Y human neuroblastoma cell cultures. Molecules were
designed by classical bioisosteric replacement, aiming for
desirable physiochemical properties and chemical diver-
sity. GCM PAMs were assayed for cGMP elevation and
reversal of neurotoxicity induced by 6-hydroxydopamine
in dopaminergic neuronal cells. One GCM PAM, active in
cell culture, was further tested for the reversal of memory
deficits in mice treated with scopolamine, and drug levels
in brain and plasma measured. The ligand binding site for
sGC stimulators and GCM PAMs on the sGC protein
remains to be definitively defined. Photoaffinity probes
were designed that retained the activity of the parent
GCM PAM in cell cultures in order to elucidate the bind-
ing mode to sGC and to indicate other protein partners
for such compounds.
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